What are the uses of Zoladex 3.6mg?

This is an automatically translated article.

Zoladex 3.6mg drug containing the active ingredient goserelin acetate is indicated in the treatment and control of prostate cancer, breast cancer in premenopausal women... Let's learn about the uses and dosage of Zoladex. through the article below.

1. Uses of Zoladex 3.6mg

1.1. Indications "What effects does Zoladex have?". Zoladex 3.6mg medicine contains the active ingredient goserelin acetate is indicated in the treatment of the following medical conditions:
Prostate cancer pathology: The drug helps control prostate cancer appropriate to treatment response. through hormonal mechanisms; Breast cancer pathology: Drugs that help control breast cancer in premenopausal and premenopausal women are suitable for response to hormone therapy; Endometriosis: Zoladex is used to control endometriosis, relieve symptoms including pain, and reduce the number and size of ectopic endometrial lesions. place; Reducing the thickness of the endometrium: The drug is used to reduce the thickness of the endometrium before performing endometrial ablation; Uterine fibroids: Zoladex is used in combination in preoperative iron supplementation therapy to improve hematologic status in patients with anemia caused by uterine fibroids; Assisted fertility therapy: Medications that help regulate pituitary suppression in preparation for multiple ovulation. 1.2. Pharmacokinetics Gosereline acetate is a synthetic active substance structurally similar to natural LHRH, long-term use leads to inhibition of pituitary LH secretion, which reduces serum testosterone levels in men and estradiol concentrations in men. female serum.
The effect of Gosereline is reversible upon discontinuation of treatment. As with other LHRH agonists, it may temporarily increase male testosterone and female estradiol levels. During the initial phase of treatment, some female patients may experience vaginal bleeding of varying degrees and duration, possibly due to discontinuation of estrogen therapy, which will spontaneously cease.
For men treated with Zoladex 3.6mg for approximately 21 days after the first parenteral dose, testosterone levels decreased to levels comparable to those in orchiectomy patients and this was maintained. maintained when treatment is continued every 28 days. This inhibitory effect leads to prostate tumor regression, which improves symptoms in the majority of patients.

For women treated with Zoladex, estradiol concentrations decreased approximately 21 days after the first dose and with continuous treatment every 28 days, inhibitory concentrations were comparable to those in postmenopausal women. This reduction in levels is associated with treatment response in endometriosis, hormone-dependent breast cancer, decreased oocyte growth in the ovary, and uterine fibroids. The drug will reduce endometrial thickness and may lead to amenorrhea in treated patients.
For female patients with anemia due to uterine fibroids, Zoladex combined with iron causes amenorrhea, improves hemoglobin concentration and other related hematological parameters. This combination resulted in mean hemoglobin levels approximately 1 g/dl higher than iron monotherapy.
1.3. Pharmacokinetics Zoladex 3.6mg is rapidly and completely absorbed after injection. Therefore, the bioavailability of the drug is considered perfect. A depot drug administered every 4 weeks ensures that effective concentrations are maintained and does not cause tissue accumulation.
The half-life of Zoladex 3.6mg is 2-4 hours in subjects with normal renal function, this parameter will be increased in patients with impaired renal function.
For a monthly extended release formulation, the change in drug concentration is almost negligible. Therefore, it is not necessary to change the dose in patients with impaired renal function. There were no significant pharmacokinetic changes in patients with hepatic impairment.

2. Dosage of Zoladex 3.6mg

Zoladex 3.6mg is administered subcutaneously, for the delayed release form, administered subcutaneously before 28 days. Dosage depends on the patient and the medical condition as follows:
Assisted reproduction:
Zoladex 3.6mg helps to regulate and suppress the pituitary gland with the dose determined based on the serum estradiol concentration. serum estradiol concentration at the beginning of oogenesis (about 150pmol/l). This effect lasts about 7 to 21 days; No dose adjustment is required in patients with hepatic impairment, renal impairment and the elderly. Endometriosis : The duration of drug treatment is about 6 months (because there are no clinical data for a longer course). Do not take Zoladex 3.6mg multiple times a day due to the risk of bone mineral loss. Patients treated for endometriosis with Zoladex 3.6mg plus hormone replacement therapy (progesterone and estrogen daily) showed vasomotor symptoms and reduced bone mineral loss.
Decreased endometrial thickness: Zoladex extended release is given about 4 weeks apart. The time to perform surgery was determined from the first week to the second week after taking the 2nd dose of extended-release drug.
Anemia caused by uterine fibroids: Iron is indicated for 3 days. month before surgery.
Children: The drug is not indicated in the treatment of children.

3. Zoladex 3.6mg . side effects

Zoladex 3.6mg may cause some side effects as follows:
Common side effects (ADR > 1/100):
Psychiatric: Depression, mood swings, sexual impairment; Blood vessels: Abnormal blood pressure, hot flushes; Skin: Pimples, increased sweating, hair loss; Genitourinary: Vaginal dryness, erectile dysfunction, female emulsification, breast enlargement; Reaction at the injection site; Nutrition and metabolism: Impaired glucose tolerance; Nervous system: Spinal cord compression, paresthesia, headache; Cardiovascular: Myocardial infarction , heart failure; Connective tissue and musculoskeletal: Arthralgia, bone pain; Weight gain, loss of bone density. Uncommon side effects:
Hypersensitivity to the drug; Athritis; Ureteral obstruction, breast tenderness, hypercalcemia. Rare side effects: Ovarian cysts, hypersensitivity reactions, ovulatory hyperstimulation syndrome.
Very rare side effects: Pituitary hemorrhage, pituitary tumor, psychosis.
Side effects of unknown frequency: Hair loss, uterine fibroid degeneration.
In case of occurrence of side effects, the patient should stop using the drug and notify the treating doctor or go to the nearest medical facility for timely treatment.

4. Note when using Zoladex 3.6mg

4.1. Contraindications Contraindicated to use Zoladex 3.6mg in the following cases:
People with a history of sensitivity to substances structurally similar to LHRH or any of the excipients of the drug; Women who are pregnant or breastfeeding. 4.2. Precautions for use Use caution when using the drug in men at risk of spinal cord compression or progressive urinary obstruction. These cases should be carefully monitored during the first month of treatment. Zoladex 3.6mg in particular and LHRH agonists in general can reduce bone mineral density. Studies in female patients have shown that most bone loss is reversible upon discontinuation of therapy. The use of Zoladex 3.6mg with tamoxifen in breast cancer patients may reduce bone mineral loss. Patients treated for endometriosis with Zoladex 3.6mg in combination with hormone replacement therapy have been shown to reduce bone mineral loss and vasomotor symptoms. The drug should be used with caution in women with metabolic bone disease and in patients with cervical dilation because the drug may cause increased cervical resistance. In assisted reproductive therapy, Zoladex 3.6mg should only be used as part of an assisted reproductive regimen under the supervision of experienced physicians. Caution should be exercised when using ART in patients with polycystic ovary syndrome because stimulation of follicular development may be increased. Pregnant women: Zoladex 3.6mg should not be used in the treatment of pregnant women because of the proven risk of miscarriage or fetal abnormalities. Lactation: Do not use Zoladex 3.6mg in women who are breastfeeding. Drivers and machine operators: The drug does not affect the patient's ability to drive or operate machinery. Zoladex 3.6mg medicine contains the active ingredient goserelin acetate which is indicated in the treatment and control of prostate cancer, breast cancer in premenopausal women. To ensure the effectiveness of treatment and avoid side effects, patients need to take medicine according to prescription or consult a doctor, pharmacist for advice.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.